Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod plus HPV vaccination vs imiquimod alone in usual-type VIN
2008-008251-42Phase 2Active
- Sponsor
- Erasmus MC
- Start
- Jan 2009
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of qHPV vaccine and imiquimod in vulvar intraepithelial neoplasia (VIN) and vulvar carcinoma in situ (2 arms), sponsored by Erasmus MC. Primary endpoints: Clinical response in VIN lesions, Absence of HPV DNA in VIN lesions and 2 more. Started Jan 2009; status: active.
02
Drugs
qHPV vaccineimiquimod
03
Conditions
vulvar intraepithelial neoplasia (VIN)vulvar carcinoma in situ
Beyond the preview
Go deeper on 2008-008251-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008251-42.